<DOC>
	<DOCNO>NCT00485719</DOCNO>
	<brief_summary>The purpose study determine safety tolerability XL765 . XL765 new chemical entity inhibit kinase PI3K mTOR . In preclinical study , inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell , whereas inactivation mTOR show inhibit growth tumor cell .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics XL765 ( SAR245409 ) Adults With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>The subject histologically confirm metastatic unresectable solid tumor standard curative palliative measure exist longer effective , therapy know prolong survival . The subject disease assessable tumor marker , physical , radiologic mean . The subject least 18 year old . The subject 's weight lease 40 kg . The subject Eastern Cooperative Oncology Group performance status 0 2 . The subject adequate organ bone marrow function . The subject fasting plasma glucose &lt; 120 mg/dL screening . subject enrol Expanded MTD Cohort LowerDose Tumor Genetic Alteration Subjects : 1. tumor tissue amenable serial biopsy ; 2. additional inform consent The subject capable understanding protocol sign informed consent . Sexually active subject ( male female ) must use medically acceptable method contraception course study . Female subject childbearing potential must negative serum pregnancy test screening . If subject receive 3 prior regimen cytotoxic chemotherapy , 2 biologic regimen , 3000 cGy &gt; 25 % bone marrow , sponsor must determine subject suitability enrollment . The subject diagnosis malignancy ( unless nonmelanoma skin cancer , situ carcinoma cervix , malignancy diagnose â‰¥ 2 year ago , evidence disease 2 year prior screen study . ) The subject receive anticancer treatment ( chemotherapy , radiotherapy , cytokine , hormone ) within 30 day ( 6 week nitrosoureas , mitomycin C , bicalutamide ) first dose XL765 . The subject receive radiation &gt; 25 % bone marrow . The subject recover adverse event , except Grade 2 alopecia , due investigational agent administer prior study enrollment . The subject receive another investigational agent within 30 day first dose XL765 smallmolecule kinase inhibitor within 14 day 5 halflives . The subject know diabetes The subject uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . The subject psychiatric illness/social situation would limit compliance study requirement . The subject pregnant breast feeding . The subject know positive HIV . The subject know allergy hypersensitivity component XL765 formulation . The subject baseline correct QT interval &gt; 450 m .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>